Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 1/20 | 0.56 |
| ▸ | ABL1 | P00519 | 1/20 | 0.56 |
| ▸ | PPARG | P37231 | 1/20 | 0.56 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.56 |
| ▸ | MCHR1 | Q99705 | 10/20 | 0.45 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.44 |
| ▸ | DAO | P14920 | 3/20 | 0.44 |
| ▸ | SCN8A | Q9UQD0 | 3/20 | 0.43 |
| ▸ | SCN10A | Q9Y5Y9 | 3/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL989400 | 0.82 | MRGPRX4 (0.44) | MCHR1MRGPRX4DAOGRM2 | |
| SCHEMBL3477099 | 0.81 | NSD2 (0.66) | NSD2ABL1PPARGRIN1L3MBTL1 | |
| SCHEMBL94265 | 0.80 | NSD2 (0.60) | NSD2ABL1PPARGRIN1L3MBTL1 | |
| SCHEMBL15768793 | 0.79 | NSD2 (0.49) | NSD2ABL1PPARGRIN1L3MBTL1 | |
| SCHEMBL15111297 | 0.77 | NSD2 (0.64) | NSD2ABL1PPARGRIN1L3MBTL1 | |
| SCHEMBL1003510 | 0.76 | NSD2 (0.71) | NSD2ABL1PPARGRIN1L3MBTL1 | |
| SCHEMBL15769394 | 0.75 | NSD2 (0.51) | NSD2ABL1PPARGRIN1L3MBTL1 | |
| SCHEMBL4232057 | 0.74 | NSD2 (0.68) | NSD2ABL1PPARGRIN1L3MBTL1 | |
| SCHEMBL4047944 | 0.74 | NSD2 (0.49) | NSD2ABL1PPARGRIN1L3MBTL1 | |
| SCHEMBL14151016 | 0.73 | NSD2 (0.63) | NSD2ABL1PPARGRIN1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170204095-A1 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | APOLLO ADMINISTRATIVE AGENCY LLC, AS SUCCESSOR AGENT | 2017-07-20 | — | — | US | disclosed |
| US-20170204095-A1 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | APOLLO ADMINISTRATIVE AGENCY LLC, AS SUCCESSOR AGENT | 2017-07-20 | — | — | US | disclosed |
| US-9650378-B2 | (1-azinone)-substituted pyridoindoles | ALBANY MOLECULAR RESEARCH, INC. (US) | 2017-05-16 | — | — | US | disclosed |
| US-9650378-B2 | (1-azinone)-substituted pyridoindoles | ALBANY MOLECULAR RESEARCH, INC. (US) | 2017-05-16 | — | — | US | disclosed |
| US-20160159798-A1 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | HARMONY BIOSCIENCES, LLC | 2016-06-09 | — | — | US | disclosed |
| US-20160159798-A1 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | HARMONY BIOSCIENCES, LLC | 2016-06-09 | — | — | US | disclosed |
| US-9296743-B2 | (1-azinone)-substituted pyridoindoles | ALBANY MOLECULAR RESEARCH, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-9073925-B2 | Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof | ALBANY MOLECULAR RESEARCH, INC. (US) | 2015-07-07 | — | — | US | disclosed |
| US-9073925-B2 | Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof | ALBANY MOLECULAR RESEARCH, INC. (US) | 2015-07-07 | — | — | US | disclosed |
| US-8993765-B2 | Tetrahydro-azacarboline MCH-1 antagonists, methods of making, and uses thereof | ALBANY MOLECULAR RESEARCH, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20110003739-A1 | AZINONE-SUBSTITUTED AZABICYCLOALKANE-INDOLE AND AZABICYCLOALKANE-PYRROLO-PYRIDINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| US-20100331339-A9 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | ALBANY MOLECULAR RESEARCH, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331339-A9 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | ALBANY MOLECULAR RESEARCH, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331339-A9 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | ALBANY MOLECULAR RESEARCH, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| EP-2240481-A1 | (1-AZINONE) -SUBSTITUTED PYRIDOINDOLES AS MCH ANTAGONISTS | Albany Molecular Research, Inc. (US) | 2010-10-20 | — | — | EP | disclosed |
| US-20090275590-A1 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | ALBANY MOLECULAR RESEARCH, INC. (US) | 2009-11-05 | — | — | US | disclosed |
| US-20090275590-A1 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | ALBANY MOLECULAR RESEARCH, INC. (US) | 2009-11-05 | — | — | US | disclosed |
| US-20090275590-A1 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | ALBANY MOLECULAR RESEARCH, INC. (US) | 2009-11-05 | — | — | US | disclosed |
| WO-2009089482-A1 | (1-AZINONE) -SUBSTITUTED PYRIDOINDOLES AS MCH ANTAGONISTS | ALBANY MOLECULAR RESEARCH, INC. (US) | 2009-07-16 | — | — | WO | disclosed |
| WO-2009089482-A1 | (1-AZINONE) -SUBSTITUTED PYRIDOINDOLES AS MCH ANTAGONISTS | ALBANY MOLECULAR RESEARCH, INC. (US) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331339-A9 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | NR3C2, NR0B1, NR3C1 | NSD2 3390/4885ABL1 985/4885PPARG 181/4885 |
| US-20110003739-A1 | AZINONE-SUBSTITUTED AZABICYCLOALKANE-INDOLE AND AZABICYCLOALKANE-PYRROLO-PYRIDINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF | MCHR1, MCHR2, TAAR1 | NSD2 2998/4885ABL1 2714/4885PPARG 1379/4885 |
| US-20170204095-A1 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | NR3C2, NR2E3, NR0B1 | NSD2 3647/4885ABL1 1074/4885PPARG 172/4885 |
| US-20090275590-A1 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | NR3C2, NR0B1, NR3C1 | NSD2 3390/4885ABL1 985/4885PPARG 181/4885 |
| US-20160159798-A1 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | NR3C2, NR2E3, NR0B1 | NSD2 3647/4885ABL1 1074/4885PPARG 172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.